Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis

Methotrexate is the gold-standard DMARD in rheumatoid arthritis but is often associated with “mild” adverse effects like intolerance or laboratory abnormalities. Although non-life threatening, they are responsible for drug discontinuation in 17–50%. There is limited data on clinical and genetic markers that predict their occurrence. This prospective study enrolled patients with active rheumatoid arthritis. They were started on methotrexate at a...